Royalty Pharma plc Class A Ordinary Shares
RPRX
$60.96
+2.25%
Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, acquiring rights to receive payments tied to the sales of approved and development-stage medicines rather than operating its own commercial infrastructure. Its portfolio spans more than 35 commercial products — including royalties on AbbVie/J&J's Imbruvica, Biogen's Tysabri, and Vertex's cystic fibrosis franchise — plus roughly 10 development-stage candidates, giving it a diversified, annuity-like revenue stream across therapeutic areas. The company's distinct identity rests on its role as a capital provider to the biopharma ecosystem: it monetizes royalty streams for drug developers and academic institutions, effectively acting as a specialty finance platform with pharma-like economics and a very small headcount of approximately 100 employees. The current investor narrative centers on the durability and growth of its royalty portfolio, the deployment of capital into new royalty acquisitions, and the stock's dramatic re-rating over the past year as investors have gravitated toward its low-beta, cash-generative profile amid a strong absolute and relative performance run.…
RPRX
Royalty Pharma plc Class A Ordinary Shares
$60.96
Investment Opinion: Should I buy RPRX Today?
Rating: Buy (moderate conviction). The thesis is that RPRX is a low-beta, high-margin royalty compounder still trading at a reasonable forward valuation — a forward PE of 10.51x against a PEG of 0.776 — with unanimous strong-buy coverage and a $65.38 average target implying 7.2% upside. The analyst consensus (mean rating 1.5 across eight analysts) anchors the view that the risk/reward remains favorable even after the run.
The supporting evidence is concrete: revenue grew 16.5% year-over-year to $674.1 million in Q2 2026; operating margin is 65.58% with a 100% TTM gross margin; TTM free cash flow is $2.98 billion; the 2.27% dividend is covered at a 49.1% payout ratio; and the forward PE of 10.51x is 37% below the trailing 16.58x. The PS ratio of 7.02x sits well below historical quarterly readings that ranged up to roughly 37.0x, and EV/EBITDA of 15.30x is reasonable for a high-margin healthcare compounder.
The biggest risks that could invalidate the thesis are recurring earnings volatility (Q2 2026 EPS of $0.04 versus Q1's $0.68), leverage at 1.38x debt-to-equity with a 0.97 current ratio, and the thin 7.2% implied upside that leaves little margin for error. This Buy would upgrade to a stronger conviction if forward EPS of $7.90 is confirmed by normalized quarterly results, and would downgrade to Hold if revenue growth decelerates below 10% or if interest expense keeps suppressing net margins near the 2.65% quarterly level. Verdict: fairly valued to modestly undervalued on forward earnings, but no longer a deep-value entry after the 67.75% one-year re-rating.
Sign up to view all
RPRX 12-Month Price Forecast
The forward-looking view is constructive but tempered by the stock's recent run. A 10.51x forward PE against a $7.90 consensus EPS estimate and a 0.776 PEG suggests the market is not overpaying for the royalty annuity, while 16.5% revenue growth and $2.98 billion in TTM free cash flow underwrite the dividend and continued acquisitions. The main uncertainty is earnings quality: Q2 2026's $0.04 EPS versus Q1's $0.68 shows financing and mark-to-market effects can distort results, and the 7.2% implied upside to the $65.38 average target limits near-term reward. I would upgrade to high confidence if two consecutive quarters confirm EPS trending toward $7.90, and downgrade to neutral if revenue growth slips below 10% or the stock breaks the $56–57 support zone.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Royalty Pharma plc Class A Ordinary Shares's 12-month outlook, with a consensus price target around $65.38 and implied upside of +7.2% versus the current price.
Average Target
$65.38
0 analysts
Implied Upside
+7.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$61 - $70
Analyst target range
Eight analysts cover RPRX, and the consensus is decisively bullish with a "strong_buy" recommendation and a mean rating of 1.5 (where 1.0 is a strong buy). The average target price of $65.38 implies approximately 7.2% upside from the current $60.96 price, a modest but positive expected return. The consensus leans clearly bullish, supported by the analyst EPS estimate of $7.90 and revenue estimate of $5.10 billion, and the institutional ratings history shows a pattern of reiterations rather than downgrades — TD Cowen, JP Morgan, Citigroup, UBS, and Morgan Stanley have all maintained Buy or Overweight ratings through 2026, with UBS upgrading from Neutral to Buy in January 2026.
The target range spans $61.00 to $70.00, a relatively tight 14.8% spread that signals strong analyst conviction and low dispersion of views. The high target of $70.00 (14.8% above the current price) likely assumes continued royalty portfolio expansion, multiple expansion toward the higher end of its historical range, and successful deployment of capital into new royalty acquisitions. The low target of $61.00 is essentially at the current price, implying minimal downside even in a bear case — a reflection of the stock's low beta (0.412) and defensive cash-flow characteristics. The tight spread and unanimous bullish stance suggest limited near-term catalyst risk, though the modest 7.2% implied upside means much of the good news may already be reflected in the price.
Drowning in data?
Find the real signal!
Bulls vs Bears: RPRX Investment Factors
The bull case currently holds stronger evidence: 16.5% revenue growth, $2.98 billion in TTM free cash flow, a 65.58% operating margin, a forward PE of 10.51x, a PEG of 0.776, and unanimous strong-buy coverage with a $65.38 average target all point to a durable, cash-generative compounder that is still reasonably priced on forward earnings. The bears' strongest points are earnings volatility (Q2 2026 EPS of $0.04 versus Q1's $0.68) and the thin 7.2% implied upside after a 67.75% one-year run. The single most important tension is whether the forward EPS estimate of $7.90 — which underpins the entire low-forward-PE argument — is actually delivered; if quarterly earnings normalize and interest costs stay contained, the stock is cheap, but if Q2-style charges recur, the valuation case weakens materially.
Bullish
- Decisive relative strength vs. market: RPRX is up 67.75% over the trailing year versus SPY's 15.53%, a 52.22 percentage point relative strength advantage, and 56.87% YTD versus SPY's 11.93%. This is not a marginal outperformance — it reflects a structural re-rating of the low-beta royalty model, with beta of just 0.412 and a max drawdown of only -12.12%.
- Forward PE of 10.5x with sub-1.0 PEG: The forward PE of 10.51x sits 37% below the trailing PE of 16.58x, implying the market expects earnings to more than double toward the $7.90 consensus EPS estimate. The PEG ratio of 0.776 is below 1.0, suggesting the stock is inexpensive relative to expected growth despite the 67.75% one-year price gain.
- Mid-teens revenue growth on annuity base: Q2 2026 revenue of $674.1 million grew 16.5% year-over-year from $578.7 million, extending a steady climb from $568.2 million in Q1 2025. The royalty model delivers this growth with a 65.58% operating margin and roughly 100 employees, giving it operating leverage few pharma peers can match.
- Strong free cash flow and covered dividend: TTM free cash flow is $2.98 billion, with Q2 2026 contributing $686.2 million and Q1 2026 $760.5 million. The 2.27% dividend yield carries a 49.1% payout ratio, leaving ample room for both continued royalty acquisitions and shareholder returns.
Bearish
- Earnings quality is highly volatile: Q2 2026 net income collapsed to $17.9 million (EPS $0.04) from $295.0 million in Q1 2026 (EPS $0.68), a 2.65% quarterly net margin versus the 32.42% TTM figure. The swing was driven by a $268.2 million cost-of-revenue charge and $93.6 million interest expense, showing how financing and mark-to-market effects can overwhelm operating results.
- Leverage is structural, not temporary: Debt-to-equity of 1.38x and a current ratio of 0.97 — below 1.0 — mean short-term liabilities exceed current assets. Because royalty acquisitions are debt-funded, this leverage is a permanent feature of the business model, and interest expense of roughly $93.6 million per quarter directly competes with net income.
- Modest implied upside after a big run: The average analyst target of $65.38 offers only 7.2% upside from $60.96, and the stock already trades at roughly 86% of its 52-week range ($35.92–$64.38). With the shares 5.3% below the high, much of the re-rating appears priced in, limiting near-term reward relative to risk.
- Momentum is decelerating: The 1-month gain of 4.26% and 3-month gain of 4.78% are far smaller than the 21.92% six-month and 67.75% one-year advances. The stock also pulled back from a $63.96 early-September peak to the $56–57 area in early October, a classic momentum-normalization pattern after a strong run.
RPRX Technical Analysis
RPRX is in a sustained, powerful uptrend, with the shares up 67.75% over the trailing year versus a 15.53% gain for SPY — a relative strength advantage of 52.22 percentage points. At a current price of $60.96, the stock sits at roughly 86% of its 52-week range (low $35.92, high $64.38), positioning it in the upper portion of its band but still about 5.3% below the high. This location near the top of the range signals persistent momentum rather than an overextended blow-off top, though it does mean the stock is no longer a deep-value entry point. The year-to-date gain of 56.87% versus SPY's 11.93% underscores how decisively the market has re-rated this name.
Short-term momentum is positive but decelerating relative to the longer-term trend. The stock is up 4.26% over the past month and 4.78% over three months, both ahead of SPY's 1.22% and 2.69% respectively, but the 1-month and 3-month gains are far smaller than the 21.92% six-month and 67.75% one-year advances — a classic pattern of momentum normalization after a strong run. The most recent session showed a 2.25% jump from a $59.62 close to $60.96, suggesting buyers are re-engaging after a September pullback from the $63.96 early-September peak to the $56-57 area in early October. The 1-month relative strength of 3.04 versus SPY confirms the stock is still outperforming, but the deceleration in the pace of gains argues for watching whether the recent bounce can reclaim the prior high.
Key technical levels are well defined: support sits at the 52-week low of $35.92, with a nearer-term support shelf around the $56-57 area that held in early October, while resistance is the 52-week high of $64.38. A breakout above $64.38 would confirm the uptrend's continuation and likely draw momentum buyers, whereas a breakdown below the $56 support zone would signal a deeper mean-reversion move toward the mid-$50s. The stock's beta of 0.412 is a critical risk-management input — it implies roughly 60% less volatility than the broad market, consistent with the modest -12.12% maximum drawdown, meaning position sizing can be larger for a given risk budget but also that the stock may lag sharply in a high-beta rally.
Beta
0.41
0.41x market volatility
Max Drawdown
-12.1%
Largest decline past year
52-Week Range
$36-$64
Price range past year
Annual Return
+67.7%
Cumulative gain past year
| Period | RPRX Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | +0.2% |
| 3m | +4.8% | +2.9% |
| 6m | +21.9% | +8.4% |
| 1y | +67.7% | +14.9% |
| ytd | +56.9% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RPRX Fundamental Analysis
Revenue is growing at a healthy clip: Q2 2026 revenue of $674.1 million rose 16.5% year-over-year from $578.7 million in Q2 2025, extending a multi-quarter expansion from $568.2 million in Q1 2025 through $630.6 million in Q1 2026 and $622.0 million in Q4 2025. The revenue mix is dominated by financial royalty assets at $638.0 million, with other royalty income contributing $36.1 million, reflecting the portfolio's concentration in a core set of blockbuster royalty streams. This steady, mid-teens growth trajectory supports the investment case as a compounding royalty annuity, though the growth rate is more modest than the stock's 67.75% one-year price appreciation, implying the re-rating has been multiple-driven as much as earnings-driven.
Profitability is robust at the operating line but noisy at the net line. Gross margin is reported at 100% on a TTM basis (with Q2 2026 gross margin of 60.2% reflecting a $268.2 million cost-of-revenue charge), and the operating margin is an exceptional 65.58%, consistent with the royalty model's minimal cost structure. However, Q2 2026 net income collapsed to $17.9 million (EPS $0.04) from $295.0 million in Q1 2026, driven by a $93.6 million interest expense and a $51.6 million net other-expense swing, producing a thin 2.65% quarterly net margin versus the 32.42% TTM net margin. The volatility in quarterly earnings — Q1 2026 EPS of $0.68 versus Q2's $0.04 — reflects mark-to-market and financing effects rather than operating deterioration, but investors should monitor whether interest costs continue to pressure the bottom line.
Balance sheet and cash flow metrics are solid but leverage is meaningful. Debt-to-equity stands at 1.38x, with a current ratio of 0.97 that is slightly below 1.0 and warrants attention for short-term liquidity, though the royalty business generates predictable cash. Free cash flow TTM is a strong $2.98 billion, and the Q2 2026 free cash flow of $686.2 million plus Q1's $760.5 million demonstrate consistent cash generation; the dividend yield of 2.27% with a payout ratio of 49.1% is well covered. ROE of 11.90% and ROA of 5.09% are respectable for a capital-intensive royalty acquirer, and the $812 million cash balance provides a buffer, but the reliance on debt to fund royalty acquisitions means the 1.38x leverage is a structural feature investors must underwrite.
Quarterly Revenue
$674141000.0B
2026-06
Revenue YoY Growth
+16.5%
YoY Comparison
Gross Margin
60.2%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RPRX Overvalued?
Because net income is positive (TTM EPS of $0.046 and net margin of 32.42%), the PE ratio is the appropriate primary metric. The trailing PE of 16.58x compares with a forward PE of just 10.51x — a striking 37% compression that implies the market expects earnings to more than double, consistent with the analyst consensus EPS estimate of $7.90 versus the current trailing figure. This wide trailing-to-forward gap signals that the market is pricing in substantial earnings growth, likely from royalty portfolio expansion and the normalization of quarterly earnings that were depressed by financing costs in Q2 2026.
On a peer comparison basis, the stock's PS ratio of 7.02x and EV/Sales of 14.84x look elevated relative to a typical pharmaceutical sector, though the royalty model's 65.58% operating margin and 100% gross margin justify a premium to traditional drugmakers. The PEG ratio of 0.78 is notably below 1.0, suggesting the stock is inexpensive relative to its expected growth rate, while the EV/EBITDA of 15.30x is reasonable for a high-margin, low-beta healthcare compounder. The 2.58x price-to-book is modest for a company with an 11.90% ROE, and the 2.27% dividend yield adds a income component that many growth-oriented pharma peers lack.
Historically, RPRX's valuation has been volatile: the PE ratio ranged from 4.74x in Q4 2023 to 346.97x in Q2 2026 (distorted by a depressed quarterly earnings base), while the PS ratio has ranged from roughly 19.2x in Q4 2024 to 37.0x in Q2 2026. The current PS of 7.02x on the key-metrics basis is well below the historical quarterly PS readings, suggesting the stock is not stretched on a sales basis, while the forward PE of 10.51x sits near the lower end of its historical band. This combination — low forward PE, sub-1.0 PEG, and a PS below historical norms — suggests the market is not pricing in overly optimistic expectations despite the strong price run, though the trailing PE's distortion by quarterly earnings volatility limits its usefulness.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings volatility and leverage. Q2 2026 net income of $17.9 million (EPS $0.04) versus Q1 2026's $295.0 million (EPS $0.68) shows how a $268.2 million cost-of-revenue charge and $93.6 million in quarterly interest expense can gut the bottom line even as revenue grows 16.5%. Debt-to-equity of 1.38x and a current ratio of 0.97 mean the debt-funded acquisition model leaves little short-term liquidity cushion, and the portfolio's concentration in a core set of blockbuster royalty streams ($638.0 million of Q2 revenue from financial royalty assets) means any single product's sales miss flows directly to the top line.
Market and competitive risks are dominated by valuation compression and the stock's own success. After a 67.75% one-year gain and 56.87% YTD advance, the stock trades at 7.02x sales and 14.84x EV/Sales — premiums that assume the royalty portfolio keeps compounding. Beta of 0.412 cuts both ways: it cushioned the drawdown to -12.12%, but it also means the stock may lag badly in a high-beta rally and offers little hedge if rates rise and defensive healthcare cash flows de-rate. Competitive risk comes from rival royalty buyers bidding up acquisition prices and from patent cliffs or generic entry on key products such as Imbruvica, which would erode the annuity base.
The worst-case scenario is a convergence of earnings disappointment and multiple compression: a quarter where royalty acquisition spending fails to translate into revenue growth, interest costs stay near $93.6 million, and the forward EPS estimate of $7.90 is cut. In that chain, the stock could retrace toward its 52-week low of $35.92, a decline of roughly 41% from the current $60.96, or at minimum toward the $56–57 support shelf that held in early October, about a 7–8% drop. The analyst low target of $61.00 offers little protection because it sits at the current price, so the realistic downside in an adverse scenario is -8% to the support zone and up to -41% in a full mean-reversion to the 52-week low.
FAQ
The most severe risk is earnings volatility: Q2 2026 net income fell to $17.9 million (EPS $0.04) from $295.0 million in Q1 2026, driven by a $268.2 million cost-of-revenue charge and $93.6 million interest expense, producing a 2.65% quarterly net margin versus 32.42% TTM. Second is leverage: debt-to-equity of 1.38x and a current ratio of 0.97 mean the debt-funded acquisition model leaves a thin liquidity cushion. Third is valuation compression after a 67.75% one-year run — at 7.02x sales and 14.84x EV/Sales, any slowdown in royalty acquisition deployment could de-rate the stock, and beta of 0.412 offers little protection if defensive healthcare names fall out of favor. Fourth is portfolio concentration: $638.0 million of Q2 revenue came from financial royalty assets tied to a core set of blockbusters, so generic entry or a sales miss on a product like Imbruvica would hit the annuity base directly.
The 12-month outlook has three scenarios. The base case (55% probability) targets $63–$66, aligned with the $65.38 analyst average, assuming revenue growth holds near 16.5% and forward EPS of $7.90 is broadly achieved. The bull case (25%) targets $68–$70, matching the analyst high target, on accelerated royalty acquisitions and a breakout above the $64.38 52-week high. The bear case (20%) targets $36–$57, anchored to the $35.92 52-week low, if another Q2-style earnings shock triggers downgrades and a break of the $56–57 support shelf. The base case is most likely because the forward PE of 10.51x and PEG of 0.776 already reflect reasonable expectations, and the unanimous strong-buy consensus with a tight $61–$70 target range signals low dispersion of analyst views.
On forward earnings, RPRX looks modestly undervalued; on trailing sales, it looks fairly to richly valued. The forward PE of 10.51x is 37% below the trailing PE of 16.58x, implying the market expects EPS to more than double toward the $7.90 consensus, and the PEG of 0.776 is below 1.0. However, the PS ratio of 7.02x and EV/Sales of 14.84x are premium multiples that reflect the 65.58% operating margin and 100% TTM gross margin of the royalty model. The current PS of 7.02x is well below historical quarterly readings that ranged up to roughly 37.0x, and EV/EBITDA of 15.30x is reasonable for a high-margin healthcare compounder. The market appears to be pricing in steady mid-teens revenue growth and successful capital deployment, not heroic assumptions — but the 67.75% one-year gain means the easy re-rating is done.
From a risk/reward perspective, RPRX offers a favorable but not exceptional setup. The average analyst target of $65.38 implies 7.2% upside, while the low target of $61.00 sits essentially at the current $60.96 price, suggesting limited perceived downside among the eight covering analysts who unanimously rate it a strong buy. The valuation supports this: a forward PE of 10.51x and PEG of 0.776 mean investors are not paying a growth premium, and the 2.27% dividend with a 49.1% payout ratio adds income. The biggest downside risk is earnings volatility — Q2 2026 EPS of $0.04 versus Q1's $0.68 shows how quickly net income can be suppressed. It is a good buy for patient, income-oriented investors with a 12-month-plus horizon who can tolerate a stock that has already run 67.75% in a year; it is less compelling for traders seeking large near-term upside.
RPRX is better suited to long-term holding than short-term trading. Its beta of 0.412 and max drawdown of -12.12% mean low volatility, which limits the payoff from short-term momentum trades, while the 2.27% dividend and 49.1% payout ratio reward patient ownership. The business is a mature, cash-generative royalty annuity — $2.98 billion in TTM free cash flow and a 65.58% operating margin — rather than a high-growth story, so earnings visibility is relatively high but upside is gradual. The stock is up 67.75% over one year and sits about 5.3% below its 52-week high, so near-term returns may be muted as momentum normalizes. A suggested minimum holding period is 12–18 months, long enough to capture the next several royalty acquisition cycles and confirm whether EPS trends toward the $7.90 consensus.
